The Coca-Cola Co K vs GeneDx Holdings Corp — how do they compare? The Coca-Cola Co K trades at $85.69 (market cap $372.08B), while GeneDx Holdings Corp trades at $82.5 (market cap $2.44B). The key difference: The Coca-Cola Co K is far larger — about 152.5× GeneDx Holdings Corp's market cap, and The Coca-Cola Co K pays a 2.45% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| KO | WGS | |
|---|---|---|
Market Cap | $372.08B | $2.44B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Technology |
52-Week High | $89.08 | $167.51 |
52-Week Low | $65.67 | $34.51 |
Enterprise Value | $399.26B | $2.48B |
Dividend Yield | 2.45% | — |
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $86.87, down 0.21% today, with a bullish technical signal supported by moving averages and RSI near 69. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations, and maintains robust profitability with a 28.56% net margin. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
KO offers a solid dividend history with 64 consecutive years of increases, but faces risks from regional demand divergence and high debt. Analysts are bullish with a $95.83 price target, implying 10% upside, though valuation multiples like P/E of 25.97 suggest premium pricing relative to peers.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →